Penumbra, Inc.
PEN · NYSE
PEN · NYSE
Penumbra develops and sells medical devices, including products for thrombectomy and neurosurgery. It earns revenue by selling its products through direct sales organizations and distributors to healthcare providers. In Q3 2026, the company reported $410.1 million in revenue, including $279.2 million from global thrombectomy; the supplied evidence does not break out the remaining revenue by business. For FY2025, Penumbra reported $1.4 billion in revenue and $0.2 billion in net income, compared with $1.2 billion in revenue and $0.0 billion in net income in FY2024. The company is based in Alameda, California.
Penumbra fell 1.68%, from $324.39 to $318.95. Shares rose to $325.22 on October 26, slipped to $324.04 the next day, then lost ground to $318.31 on October 28 as trading volume increased to 851,287 shares. They partly rebounded to $321.97 on October 29 before ending the period lower on October 30. The supplied evidence does not establish a dated company-specific catalyst for these moves: the Q3 revenue and income reports are undated here, so their timing relative to trading cannot be confirmed. No benchmark or sector performance is provided to explain the decline through broader-market context.
